Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 14 sources its claims cite were checked for support.

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Open access

Abstract

Despite the success of KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), more effective treatments are needed. One preclinical strategy has been to cotarget RAS and mTOR pathways; however, toxicity due to broad mTOR inhibition has limited its utility. Therefore, we sought to develop a more refined means of targeting cap-dependent translation and identifying the most therapeutically important eukaryotic initiation factor 4F complex-translated (eIF4F-translated) targets. Here, we show that an eIF4A inhibitor, which targets a component of eIF4F, dramatically enhances the effects of KRAS G12C inhibitors in NSCLCs and together these agents induce potent tumor regression in vivo. By screening a broad panel of eIF4F targets, we show that this cooperativity is driven by effects on BCL-2 family proteins. Moreover, because multiple BCL-2 family members are concomitantly suppressed, these agents are broadly efficacious in NSCLCs, irrespective of their dependency on MCL1, BCL-xL, or BCL-2, which is known to be heterogeneous. Finally, we show that MYC overexpression confers sensitivity to this combination because it creates a dependency on eIF4A for BCL-2 family protein expression. Together, these studies identify a promising therapeutic strategy for KRAS-mutant NSCLCs, demonstrate that BCL-2 proteins are the key mediators of the therapeutic response in this tumor type, and uncover a predictive biomarker of sensitivity.

Overview

CoChat Summary

TL;DR

eIF4A inhibition with eFT226 potently sensitizes KRAS-mutant NSCLCs to KRAS G12C or MEK inhibitors, causing apoptosis and durable tumor regression in preclinical models. The effect is driven by suppression of multiple BCL-2 family prosurvival proteins, and MYC amplification/overexpression marks sensitivity.

Key findings

  • eFT226 plus MRTX849 sensitized 75% of KRAS G12C–mutant NSCLC cell lines, with loss of approximately 60%–90% of cells within 3 days; eFT226 plus trametinib was cytotoxic in 9 of 13 KRAS-mutant lines.
  • In vivo, MRTX849 plus eFT226 caused 50%–75% tumor regression over 28 days in H23 xenografts and up to 85%–90% regression in the KRAS G12C–mutant PDX DFCI-730; eFT226 also promoted sustained regression with trametinib in KRAS G12A and G12V models.
  • The combination cooperatively triggered apoptosis in approximately 50% of sensitive cells after 48–72 hours and suppressed MCL1, BCL-xL, and/or BCL-2; resistant cells did not substantially suppress these prosurvival proteins.
  • MYC amplifications were present in 7 of 9 sensitive cell lines and 0 of 4 resistant lines; ectopic MYC expression converted all 4 resistant lines to sensitive, and high-MYC patient-derived organotypic spheroids were sensitive whereas low-MYC were resistant.

Methods

  • Human KRAS-mutant NSCLC cell lines were tested in 3D spheroid and modified 2D assays, short- and long-term proliferation assays, siRNA knockdowns, lentiviral overexpression, Western blotting, immunoprecipitation, and Incucyte live-cell caspase-3/7 apoptosis imaging.
  • Synergy was assessed with SynergyFinder using the highest single agent (HSA) model; drug treatments included eFT226, MRTX849, trametinib, navitoclax, venetoclax, S63845, and palbociclib.
  • In vivo studies used H23, H1573, H441, and H2030 xenografts and DFCI-730 PDX models; ex vivo studies used patient-derived organotypic tumor spheroids (PDOTSs) from 5 KRAS G12C–mutant lung adenocarcinoma samples, plus CCLE/cBioPortal MYC copy-number analysis and GSEA.

Limitations

  • The paper does not include a formal limitations section.
  • Evident from the text: the therapeutic strategy is preclinical, relying on cell lines, xenografts, PDX, and PDOTS models rather than clinical trial data.
  • The authors note that the triple combination of eIF4A, BCL-xL/BCL-2, and KRAS G12C inhibitors exerted the strongest cytotoxic effects but “would not likely be tolerated,” and they position eIF4Ai+KRASi as the alternative promising combination.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci167651

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 eIF4A inhibitors dramatically sensitize NSCLCs to KRAS G12C inhibitors. (A) Bar graph depicting the fold change in cell numbers after 72 hours (versus day 0) using a panel of KRAS G12C–mutant NSCLC cells grown in 3D conditions. Cells were treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), or both agents together (Combo). Data are represented as mean ± SD. n = 3. ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. (B) Representative photographs of sensitive KRAS G12C–mutant NSCLC spheroids after 72 hours of indicated drug treatments. Images were obtained using the 2X Bright Field channel. Original magnification, ×2. (C) Bar graph depicting fold change in cell numbers after 72 hours (versus day 0) in the same panel of cell lines grown in 2D tissue-culture conditions with 2% serum. Cells were treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), or both agents together (Combo). Data are represented as means ± SD. n = 3. ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test). (D) Immunoblots showing suppression of phospho-ERK by MRTX849 (KRASi, 100 nM) and/or eFT226 (eIF4Ai, 25 nM) after 24 hours of treatment. (E) Bar graphs depicting fold change in cell number of specified cell lines transfected with either siCNT or siEIF4A1 and treated with vehicle (DMSO) or 100 nM MRTX849 (KRASi) for 72 hours in 2D/low-serum conditions. Data are represented as means ± SD. n = 3. ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Immunoblots confirm suppression of eIF4A1 by siRNAs.
Figure 1 eIF4A inhibitors dramatically sensitize NSCLCs to KRAS G12C inhibitors. (A) Bar graph depicting the fold change in cell numbers after 72 hours (versus day 0) using a panel of KRAS G12C–mutant NSCLC cells grown in 3D conditions. Cells were treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), or both agents together (Combo). Data are represented as mean ± SD. n = 3. ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. (B) Representative photographs of sensitive KRAS G12C–mutant NSCLC spheroids after 72 hours of indicated drug treatments. Images were obtained using the 2X Bright Field channel. Original magnification, ×2. (C) Bar graph depicting fold change in cell numbers after 72 hours (versus day 0) in the same panel of cell lines grown in 2D tissue-culture conditions with 2% serum. Cells were treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), or both agents together (Combo). Data are represented as means ± SD. n = 3. ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test). (D) Immunoblots showing suppression of phospho-ERK by MRTX849 (KRASi, 100 nM) and/or eFT226 (eIF4Ai, 25 nM) after 24 hours of treatment. (E) Bar graphs depicting fold change in cell number of specified cell lines transfected with either siCNT or siEIF4A1 and treated with vehicle (DMSO) or 100 nM MRTX849 (KRASi) for 72 hours in 2D/low-serum conditions. Data are represented as means ± SD. n = 3. ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Immunoblots confirm suppression of eIF4A1 by siRNAs.CC BY · PubMed Central
Figure 2 eIF4A inhibitors similarly enhance the effects of MEK inhibitors. (A) Bar graph depicting fold change in cell numbers in NSCLC cell lines harboring various mutations in KRAS treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 50 nM trametinib (MEKi), or both agents together (Combo) for 72 hours in 2D/low-serum conditions. Data are represented as means ± SD. n = 3. ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. H23 (KRAS G12C), H1573 (KRAS G12A), LU99 (KRAS G12C), H1792 (KRAS G12C), HCC44 (KRAS G12C), LU65 (KRAS G12C), H441 (KRAS G12V), H1944 (KRAS G13D), H2122 (KRAS G12C), A549 (KRAS G12S), H1373 (KRAS G12C), H2030 (KRAS G12C), H1355 (KRAS G13C). (B) Immunoblots for each cell line showing suppression of phospho-ERK by trametinib (MEKi) after 24 hours. (C) Bar graphs depicting fold change in cell numbers of specified cell lines transfected with either siCNT or siEIF4A1 and treated with vehicle (DMSO) or 50 nM trametinib (MEKi) for 72 hours in 2D/low-serum conditions. Data are represented as means ± SD. n = 3. ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Immunoblots confirm suppression of eIF4A1 by siRNAs.
Figure 2 eIF4A inhibitors similarly enhance the effects of MEK inhibitors. (A) Bar graph depicting fold change in cell numbers in NSCLC cell lines harboring various mutations in KRAS treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 50 nM trametinib (MEKi), or both agents together (Combo) for 72 hours in 2D/low-serum conditions. Data are represented as means ± SD. n = 3. ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. H23 (KRAS G12C), H1573 (KRAS G12A), LU99 (KRAS G12C), H1792 (KRAS G12C), HCC44 (KRAS G12C), LU65 (KRAS G12C), H441 (KRAS G12V), H1944 (KRAS G13D), H2122 (KRAS G12C), A549 (KRAS G12S), H1373 (KRAS G12C), H2030 (KRAS G12C), H1355 (KRAS G13C). (B) Immunoblots for each cell line showing suppression of phospho-ERK by trametinib (MEKi) after 24 hours. (C) Bar graphs depicting fold change in cell numbers of specified cell lines transfected with either siCNT or siEIF4A1 and treated with vehicle (DMSO) or 50 nM trametinib (MEKi) for 72 hours in 2D/low-serum conditions. Data are represented as means ± SD. n = 3. ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Immunoblots confirm suppression of eIF4A1 by siRNAs.CC BY · PubMed Central
Figure 3 eIF4A inhibitors synergize with KRAS G12C or MEK inhibitors and trigger apoptosis in NSCLCs. (A and B) Synergy plots depicting the effects of indicated drug combinations using the HSA model. (C and D) Long-term cell proliferation assay of KRAS-mutant NSCLC cells treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), 50 nM trametinib (MEKi), or drug combinations (Combo) up to 3 weeks. (E–G) Incucyte live-cell imaging data depicting cleaved caspase-3/7 activity in sensitive H23 and H1573 and resistant H2030 cell lines in response to vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), 50 nM trametinib (MEKi), or drug combinations (Combo).
Figure 3 eIF4A inhibitors synergize with KRAS G12C or MEK inhibitors and trigger apoptosis in NSCLCs. (A and B) Synergy plots depicting the effects of indicated drug combinations using the HSA model. (C and D) Long-term cell proliferation assay of KRAS-mutant NSCLC cells treated with vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), 50 nM trametinib (MEKi), or drug combinations (Combo) up to 3 weeks. (E–G) Incucyte live-cell imaging data depicting cleaved caspase-3/7 activity in sensitive H23 and H1573 and resistant H2030 cell lines in response to vehicle (DMSO), 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), 50 nM trametinib (MEKi), or drug combinations (Combo).CC BY · PubMed Central
Figure 4 Combined eIF4A and RAS/ERK pathway inhibitors promote potent and durable responses in vivo. Graphs depicting the fold change in tumor volume of (A and B) H23-derived xenograft models and (C and D) DFCI-730 PDX models treated for 28 days with vehicle, 100 mg/kg QD MRTX849 (KRASi), 0.5 mg/kg Q4D eFT226 (eIF4Ai), or the 2 agents together (Combo). Data are represented as means ± SEM. n = 7–8 tumors per condition. (B and D) Waterfall plots depicting fold change of each tumor within the 4 treatment arms after 28 days of treatment (versus day 0). ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Single asterisks indicate maximum tumor volume. These mice reached end point at days 21 and 25. Graphs depicting the fold change in tumor volume of (E and F) H1573-derived xenograft models and (G and H) H441-derived xenograft models treated for 28 days with vehicle, 0.6 mg/kg QD trametinib (MEKi), 0.5 mg/kg Q4D eFT226 (eIF4Ai), or the 2 agents together (Combo). Data are represented as means ± SEM. n = 7–10 tumors per condition. (F and H) Waterfall plots depicting fold change of each tumor within the 4 treatment arms after 28 days of treatment (versus day 0). ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Single asterisks indicate maximum tumor volume. These mice reached end point at days 18 and 21.
Figure 4 Combined eIF4A and RAS/ERK pathway inhibitors promote potent and durable responses in vivo. Graphs depicting the fold change in tumor volume of (A and B) H23-derived xenograft models and (C and D) DFCI-730 PDX models treated for 28 days with vehicle, 100 mg/kg QD MRTX849 (KRASi), 0.5 mg/kg Q4D eFT226 (eIF4Ai), or the 2 agents together (Combo). Data are represented as means ± SEM. n = 7–8 tumors per condition. (B and D) Waterfall plots depicting fold change of each tumor within the 4 treatment arms after 28 days of treatment (versus day 0). ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Single asterisks indicate maximum tumor volume. These mice reached end point at days 21 and 25. Graphs depicting the fold change in tumor volume of (E and F) H1573-derived xenograft models and (G and H) H441-derived xenograft models treated for 28 days with vehicle, 0.6 mg/kg QD trametinib (MEKi), 0.5 mg/kg Q4D eFT226 (eIF4Ai), or the 2 agents together (Combo). Data are represented as means ± SEM. n = 7–10 tumors per condition. (F and H) Waterfall plots depicting fold change of each tumor within the 4 treatment arms after 28 days of treatment (versus day 0). ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. Single asterisks indicate maximum tumor volume. These mice reached end point at days 18 and 21.CC BY · PubMed Central
Figure 5 eIF4A and RAS pathway inhibitors cooperatively suppress the expression of prosurvival BCL-2 family proteins, cyclin D1, and CDK4. (A) Heatmap depicting protein expression of established eIF4A-regulated targets in H23- and H1944-sensitive lines after 24 hours of treatment with vehicle (DMSO) or eFT226 (eIF4Ai). Protein expression was normalized by GAPDH. Raw data from Western blots are shown in Supplemental Figure 3. (B and C) Immunoblots of MCL1, BCL-xL, BCL-2, CDK4, and cyclin D1 protein levels in sensitive cell lines after 24 hours of specified treatments. *For H1944, the loading control is the same as shown in Figure 2B because protein expression was tested using the same membrane. (D) Immunoblots of the same targets in resistant cell lines after 24 hours of specified treatments.
Figure 5 eIF4A and RAS pathway inhibitors cooperatively suppress the expression of prosurvival BCL-2 family proteins, cyclin D1, and CDK4. (A) Heatmap depicting protein expression of established eIF4A-regulated targets in H23- and H1944-sensitive lines after 24 hours of treatment with vehicle (DMSO) or eFT226 (eIF4Ai). Protein expression was normalized by GAPDH. Raw data from Western blots are shown in Supplemental Figure 3. (B and C) Immunoblots of MCL1, BCL-xL, BCL-2, CDK4, and cyclin D1 protein levels in sensitive cell lines after 24 hours of specified treatments. *For H1944, the loading control is the same as shown in Figure 2B because protein expression was tested using the same membrane. (D) Immunoblots of the same targets in resistant cell lines after 24 hours of specified treatments.CC BY · PubMed Central
Figure 6 Suppression of prosurvival proteins underlies the therapeutic response to combined eIF4A and RAS pathway inhibitors. (A) Bar graphs depicting the effects of either KRASi (left, middle) or MEKi (right) in sensitive cell lines in the presence of the indicated siRNA pools. The fold change in cell number was calculated after 72 hours of treatment (versus day 0) in response to 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. The siCDK4 studies were performed separately; however, control values were similar (primary data are shown in Supplemental Figure 4). *Complete genetic ablation of MCL1 alone in H23 cells resulted in cell death, preventing further analysis. (B) Bar graphs depicting fold changes in cell numbers in cells treated for 72 hours (versus day 0) with 100 nM S63845 (MCL1i) or 1 μM navitoclax (BCL-xL/BCL-2i) or 1 μM venetoclax (BCL-2i) combined with either 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. (C) Bar graphs depicting fold change in cell number in cells treated for 72 hours with 500 nM palbociclib (CDK4/6i) combined with either 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test.
Figure 6 Suppression of prosurvival proteins underlies the therapeutic response to combined eIF4A and RAS pathway inhibitors. (A) Bar graphs depicting the effects of either KRASi (left, middle) or MEKi (right) in sensitive cell lines in the presence of the indicated siRNA pools. The fold change in cell number was calculated after 72 hours of treatment (versus day 0) in response to 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. The siCDK4 studies were performed separately; however, control values were similar (primary data are shown in Supplemental Figure 4). *Complete genetic ablation of MCL1 alone in H23 cells resulted in cell death, preventing further analysis. (B) Bar graphs depicting fold changes in cell numbers in cells treated for 72 hours (versus day 0) with 100 nM S63845 (MCL1i) or 1 μM navitoclax (BCL-xL/BCL-2i) or 1 μM venetoclax (BCL-2i) combined with either 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test. (C) Bar graphs depicting fold change in cell number in cells treated for 72 hours with 500 nM palbociclib (CDK4/6i) combined with either 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA and Tukey’s post hoc test.CC BY · PubMed Central
Figure 7 Reconstitution with survival proteins prevents cell death in response to eIF4A and KRAS G12C inhibitors. (A) (Left) Bar graphs depicting fold changes in cell numbers of H23 and H1792 cells ectopically expressing BCL2L1 (BCL-xL), BCL2, or MCL1 cDNAs treated for 72 hours with combined 25 nM eFT226 (eIF4Ai) and 100 nM MRTX849 (KRASi). Data are represented as means ± SD. n = 3. (Right) Immunoblots confirming overexpression of BCL-xL, BCL-2, and MCL1 by cDNAs. (B) Immunoblots showing interactions of MCL1 and BCL-xL with immunoprecipitated proapoptotic BIM and BAX proteins, respectively, in response to specified drug treatments in sensitive H23 cells.
Figure 7 Reconstitution with survival proteins prevents cell death in response to eIF4A and KRAS G12C inhibitors. (A) (Left) Bar graphs depicting fold changes in cell numbers of H23 and H1792 cells ectopically expressing BCL2L1 (BCL-xL), BCL2, or MCL1 cDNAs treated for 72 hours with combined 25 nM eFT226 (eIF4Ai) and 100 nM MRTX849 (KRASi). Data are represented as means ± SD. n = 3. (Right) Immunoblots confirming overexpression of BCL-xL, BCL-2, and MCL1 by cDNAs. (B) Immunoblots showing interactions of MCL1 and BCL-xL with immunoprecipitated proapoptotic BIM and BAX proteins, respectively, in response to specified drug treatments in sensitive H23 cells.CC BY · PubMed Central
Figure 8 MYC amplification or overexpression dictates the sensitivity to combined eIF4A and RAS pathway inhibitors. (A) MYC copy-number variations (CNV) and KRAS mutational data of the 13 NSCLC cell lines retrieved from cBioPortal. (B) Immunoblots showing protein expression of MYC in NSCLC cells under baseline conditions. (C) GSEA analysis comparing the expression of MYC-regulated ribosomal and translation components in NSCLC cell lines at baseline. Heatmap shows expression of individual genes. (D) (Top) Bar graph depicting fold change in cell number of resistant NSCLC cells ectopically expressing control or MYC cDNAs treated for 72 hours with vehicle (DMSO) or combined 25 nM eFT226 (eIF4Ai) and either 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. ****P < 0.001, 1-way ANOVA and Tukey’s post hoc test. (Bottom) Immunoblots showing suppression of phospho-ERK and overexpression of MYC in response to specified treatments and MYC ectopic expression. o/e, overexpression. (E) (Left) Percentage live/dead of high MYC (DFCI-730, DFCI-456, MGH-9029-1B) and low MYC (MGH-1112-1, MGH-1196-2) PDOTSs treated with DMSO, 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), or combined drugs for 6 days in 3D microfluidic culture. (Right) Immunoblots showing protein levels of MYC in PDX tumor samples under baseline conditions.
Figure 8 MYC amplification or overexpression dictates the sensitivity to combined eIF4A and RAS pathway inhibitors. (A) MYC copy-number variations (CNV) and KRAS mutational data of the 13 NSCLC cell lines retrieved from cBioPortal. (B) Immunoblots showing protein expression of MYC in NSCLC cells under baseline conditions. (C) GSEA analysis comparing the expression of MYC-regulated ribosomal and translation components in NSCLC cell lines at baseline. Heatmap shows expression of individual genes. (D) (Top) Bar graph depicting fold change in cell number of resistant NSCLC cells ectopically expressing control or MYC cDNAs treated for 72 hours with vehicle (DMSO) or combined 25 nM eFT226 (eIF4Ai) and either 100 nM MRTX849 (KRASi) or 50 nM trametinib (MEKi). Data are represented as means ± SD. n = 3. ****P < 0.001, 1-way ANOVA and Tukey’s post hoc test. (Bottom) Immunoblots showing suppression of phospho-ERK and overexpression of MYC in response to specified treatments and MYC ectopic expression. o/e, overexpression. (E) (Left) Percentage live/dead of high MYC (DFCI-730, DFCI-456, MGH-9029-1B) and low MYC (MGH-1112-1, MGH-1196-2) PDOTSs treated with DMSO, 25 nM eFT226 (eIF4Ai), 100 nM MRTX849 (KRASi), or combined drugs for 6 days in 3D microfluidic culture. (Right) Immunoblots showing protein levels of MYC in PDX tumor samples under baseline conditions.CC BY · PubMed Central
Figure 9 MYC overexpression creates a dependency on eIF4A for the expression of prosurvival proteins. (A) Immunoblots showing MCL1, BCL-xL, and BCL-2 protein levels in response to 24 hours of specified treatments in control and MYC-overexpressing resistant lines. (B and C) Immunoblots showing interactions of MCL1 and BCL-xL with immunoprecipitated proapoptotic BIM and BAX proteins, respectively, in response to specified drug treatments in control and MYC-overexpressing resistant lines. The GAPDH immunoblots denoted by asterisks, which serve as a loading control, have been duplicated from the left side of that panel, because immunoblots were all generated from the same gel and membrane. (Right) Immunoblots confirm ectopic expression of MYC by cDNAs.
Figure 9 MYC overexpression creates a dependency on eIF4A for the expression of prosurvival proteins. (A) Immunoblots showing MCL1, BCL-xL, and BCL-2 protein levels in response to 24 hours of specified treatments in control and MYC-overexpressing resistant lines. (B and C) Immunoblots showing interactions of MCL1 and BCL-xL with immunoprecipitated proapoptotic BIM and BAX proteins, respectively, in response to specified drug treatments in control and MYC-overexpressing resistant lines. The GAPDH immunoblots denoted by asterisks, which serve as a loading control, have been duplicated from the left side of that panel, because immunoblots were all generated from the same gel and membrane. (Right) Immunoblots confirm ectopic expression of MYC by cDNAs.CC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 2 Not checked · 41 Own results and interpretations

26 more claims

Create a free account to see all 47 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 8

Create a free account to see these claims.

Citations

Cites

Show all 39 references

Cited by

See all 21

Metadata

Authors
Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., Barbie, D. A., Paweletz, C. P., Jänne, P. A., & Cichowski, K.
Affiliations
  • Brigham and Women's Hospital (US)
  • Dana-Farber Cancer Institute (US)
  • Harvard University (US)
Corresponding author
Cichowski, Karen
Venue
Journal of Clinical Investigation
Published
2023-08-15
Volume
133
Issue
16
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4382630978
Cited by
21
References
39
Citations by year
2026: 2 · 2025: 11 · 2024: 6 · 2023: 2
FWCI
3.85
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • NIH Clinical Center (R01CA111754, R35CA220497)
  • The Ludwig Center at Harvard Medical School (112762)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
KRAS G12C inhibitors, non-small cell lung cancer, eIF4F, c-Myc, Bcl-2 family proteins, cap-dependent translation, combination therapy, predictive biomarkers, Mcl-1, Bcl-xL, Bcl-2, tumor survival
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), Proto-Oncogene Proteins c-bcl-2, Eukaryotic Initiation Factor-4F, Cell Line, Tumor, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. https://app.cochat.ai/papers/10.1172/jci167651
The paper
Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., Barbie, D. A., Paweletz, C. P., Jänne, P. A., & Cichowski, K. (2023). Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci167651

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.